Clinical observation of oxycodone hydrochloride sustained-release tablets in the treatment of pain in advanced malignant tumors
10.3760/cma.j.issn.1008-6706.2020.14.004
- VernacularTitle:盐酸羟考酮缓释片治疗中晚期恶性肿瘤疼痛的临床效果观察
- Author:
Fengdan WANG
1
;
Yueli CHEN
Author Information
1. 杭州市肿瘤医院药剂科 310002
- From:
Chinese Journal of Primary Medicine and Pharmacy
2020;27(14):1679-1682
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the clinical effect of oxycodone hydrochloride sustained-release tablets in the treatment of pain in advanced malignant tumors.Methods:One hundred patients with advanced malignant tumor pain admitted to Hangzhou Cancer Hospital from June 2017 to August 2018 were selected.They were grouped according to the admission order.The observation group (50 cases) implemented oxycodone hydrochloride sustained-release tablets.The control group (50 cases) was treated with morphine sulfate sustained-release tablets.The onset time, analgesic effect, adverse reaction and KPS score were compared between the two groups.Results:The onset time [(0.79±0.22)h] of the observation group was significantly shorter than that of the control group [(2.56±1.02)h]( t=11.995, P<0.05). The total effective rate of analgesia in the observation group (98.00%) was higher than that in the control group(74.00%)( t=11.960, P<0.05). The incidence of adverse reactions in the observation group was 4.00%(2/50), which was lower than 30.00%(15/50) in the control group, (χ 2 =11.977, P<0.05). The KPS score after treatment in patients with advanced malignant tumor pain in the observation group[(79.45±1.23)points] was higher than that in the control group[(65.34±1.92)points] ( t=43.756, P<0.05). Conclusion:Oxycodone hydrochloride sustained-release tablets have significant effects in the treatment of advanced malignant tumor pain, and it is safe.
